Developing new peptide catalysts for selective chemical bond formation
Machine Learning and Automated Flow Synthesis for the Development of Peptide Catalysts for the Stereo- and Site-Selective Formation of C–C Bonds
This study is exploring new ways to create special proteins that help make important building blocks for medicines, which could lead to better and faster drug development for patients like you.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts Institute of Technology NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-11071160 on NIH RePORTER |
What this research studies
This research focuses on creating innovative peptide catalysts that can selectively form carbon-carbon bonds, which is crucial for organic synthesis and drug development. By utilizing automated fast-flow peptide synthesis and machine learning, the project aims to design peptides with unique sequences and non-natural residues that enhance their reactivity. This approach seeks to bridge the gap between traditional catalysts and novel synthetic methods, potentially leading to more efficient pharmaceutical production. Patients may benefit indirectly through advancements in drug synthesis and development.
Who could benefit from this research
Good fit: Ideal candidates for benefiting from this research are individuals with conditions that require novel therapeutic agents or improved drug formulations.
Not a fit: Patients with conditions that are not addressed by new drug development or those who do not require peptide-based therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more efficient and targeted drug development, improving treatment options for various diseases.
How similar studies have performed: Other research has shown promise in using machine learning and biocatalysts for drug synthesis, indicating a potential for success in this innovative approach.
Where this research is happening
Cambridge, United States
- Massachusetts Institute of Technology — Cambridge, United States (Active)
Researchers
- Principal investigator: Yu, Isaac Fu-Ray — Massachusetts Institute of Technology
- Study coordinator: Yu, Isaac Fu-Ray
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.